Business
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements.Hemostemix will highlight its unprecedented clinical trial results in cardiovascular disease including Chronic Limb-Threatening Ischemia (CLTI)—a field where the standard of care has remained largely unchanged for decades. With four published clinical studies validating ACP-01's ability to regenerate microvascular circulation, Hemostemix stands at the forefront of limb-preservation medicine:Peer-Reviewed CLTI Clinical Evidence PresentedHenderson et al. J Biomed Res Environ Sci. 2024 – Demonstrated restoration of perfusion and wound healing in no-option CLTI patients.Mutirangura et al. Journal of the Medical Association of Thailand, 2009 – Reported significant clinical improvements and limb salvage (83%).University of British Columbia & University of Toronto Clinical Poster Presentation, 2023 – Documented 0% mortality and improved perfusion and functional outcomes in treated CLTI patients (83%).Szabo et al. Cytotherapy, 2013 – Showed enhanced angiogenesis and sustained improvement in ischemic limb function over two years: 0% mortality and 70% limb salvage in the treated, verses 20% mortality and 75% limb loss in the normal care group.Together, these findings underscore a consistent pattern: Hemostemix's ACP-01 regenerates circulation, restores function, and improves quality of life in patients with severe ischemic peripheral arterial disease. As compared to a 50% mortality rate within five years for no option patients, the University of Toronto published VesCell generated 0% mortality and limb preservation in 83% of subjects followed for 4.5 years as a midpoint result in the phase II clinical trial. Unblinded, the 11 of 12 patients (83%) received VesCell. As published by Henderson, \"…looking at only the patients who pres...